| Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. | |
| | |
MedLine Citation:
|
PMID: 20127943 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A large body of evidence suggests that the platelet-derived growth factor (PDGF) family and associated receptors are potential targets in oncology therapeutic development because of their critical roles in the proliferation and survival of various cancers and in the regulation and growth of the tumor stroma and blood vessels. Several small molecules that nonspecifically target the PDGF signaling axis are in current use or development as anticancer therapies. However, for the majority of these agents, PDGF and its receptors are neither the primary targets nor the principal mediators of anticancer activity. IMC-3G3, a fully human monoclonal antibody of the immunoglobulin G subclass 1, specifically binds to the human PDGF receptor alpha (PDGFRalpha) with high affinity and blocks PDGF ligand binding and PDGFRalpha activation. The results of preclinical studies and the frequent expression of PDGFRalpha in many types of cancer and in cancer-associated stroma support a rationale for the clinical development of IMC-3G3. Currently, IMC-3G3 is being evaluated in early clinical development for patients with several types of solid malignancies. |
| | |
Authors:
|
Gaurav D Shah; Nick Loizos; Hagop Youssoufian; Jonathan D Schwartz; Eric K Rowinsky |
Related Documents
:
|
20705093 - Emerging nanomedicines for early cancer detection and improved treatment: current persp... 7525093 - Essential drugs for cancer chemotherapy. who consultation. 20477713 - K-ras mutation in the screening, prognosis and treatment of cancer. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Cancer Volume: 116 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-10 Completed Date: 2010-04-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 1018-26 Citation Subset: AIM; IM |
Copyright Information:
|
(c) 2010 American Cancer Society. |
Affiliation:
|
ImClone Systems Corporation, 33 ImClone Drive, Branchburg, NJ 08876, USA. gaurav.shah@imclone.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal / therapeutic use* Antineoplastic Agents / therapeutic use* Drug Delivery Systems Drug Design Humans Immunoglobulin G / therapeutic use Mice Neovascularization, Pathologic / drug therapy Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors*, immunology, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/IMC-3G3; 0/Immunoglobulin G; EC 2.7.10.1/Receptors, Platelet-Derived Growth Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Demand-specific alteration of medial prefrontal cortex response during an inhibition task in recover...
Next Document: Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibod...